GEN Exclusives

More »

GEN News Highlights

More »
Mar 17, 2011

Lonza to Provide Cell-Line and Process-Development Services for Athera’s mAb

  • Lonza will provide cell-line and process-development services for Athera Biotechnologies’ PC-mAb phosphorylcholine monoclonal antibody candidate, which the latter is developing as a treatment for preventing restenosis in patients with acute coronary syndrome. Lonza’s activities will exploit its GS Gene Expression System™ and secure a cGMP manufacturing route for Athera’s antibody candidate.

    Swedish firm Athera is one of Karolinska Development’s portfolio companies and is developing PC-mAb as a means to block the uptake of oxidized LDL in macrophages, and so effectively block the inflammatory process leading to atherosclerosis.

    Athera’s second therapeutic approach is designed to help prevent plaque rupture and atherothrombosis through increased binding of a plasma protein, annexin A5, to endothelium. The candidate is in preclinical development as a potential biopharmaceutical for treating acute coronary syndrome patients at immediate risk of acute heart attack.

    The firm already has a CE-marked diagnostic product on the market. CVDefine® is an ELISA test for detecting IgM antibodies against phosphorylcholine. Athera claims low levels of anti-PC indicates a risk for the development of cardiovascular disease, and CVDefine has been developed to provide an early indication of lesions in the artery wall caused by inflammation.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »